

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10522321
	Filing Date	2005-07-06
	First Named Inventor	BIGGADIKE, et al.
	Art Unit	1625
	Examiner Name	Aulakh, Charanjhit
	Attorney Docket Number	PG4858USw

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3994974		1976-11-30	Murakami et al.	
	2	4730008		1988-03-08	Skidmore, et al.	
	3	4853381		1989-08-01	Finch et al.	
	4	4853382		1989-08-01	Skidmore, et al.	
	5	4908386		1990-03-13	Finch et al.	
	6	4937268		1990-06-26	Skidmore, et al.	
	7	4963564		1990-10-16	Skidmore, et al.	
	8	4990505		1991-02-05	Skidmore, et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10522321
Filing Date	2005-07-06
First Named Inventor	BIGGADIKE, et al.
Art Unit	1625
Examiner Name	Aulakh, Charanjhit
Attorney Docket Number	PG4858USw

9	4992474		1991-02-12	Skidmore, et al.	
10	4997986		1991-03-05	Mitchell, et al.	
11	5099068		1992-03-24	Mitchell, et al.	
12	5109023		1992-04-28	Mitchell, et al.	
13	5283262		1994-02-01	Mitchell, et al.	
14	5552438		1996-09-03	Christensen, IV	
15	5066678		1991-11-19	Finch et al.	
16	6395738		2002-05-28	Ohshima et al.	
17	6514996		2003-02-04	Ohshima et al.	
18	6716987		2004-04-06	Ohshima et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10522321
Filing Date	2005-07-06
First Named Inventor	BIGGADIKE, et al.
Art Unit	1625
Examiner Name	Aulakh, Charanjhit
Attorney Docket Number	PG4858USw

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	2002/012829	A1	2002-09-12	Ohshima et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	69715	EP		1983-01-12	Aktiebolaget Draco		<input type="checkbox"/>
	2	220878	EP		1987-05-06	Glaxo Group Limited		<input type="checkbox"/>
	3	223410	EP		1987-05-27	Glaxo Group Limited		<input type="checkbox"/>
	4	286242	EP		1988-10-12	Glaxo Group Limited		<input type="checkbox"/>
	5	303465	EP		1989-02-15	Glaxo Group Limited		<input type="checkbox"/>
	6	317206	EP		1989-05-24	Glaxo Group Limited		<input type="checkbox"/>
	7	416951	EP		1991-03-13	Glaxo Group Limited		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10522321
Filing Date		2005-07-06
First Named Inventor	BIGGADIKE, et al.	
Art Unit	1625	
Examiner Name	Aulakh, Charanjhit	
Attorney Docket Number	PG4858USw	

8	2064336	GB		1981-06-17	Glaxo Group Limited		<input type="checkbox"/>
9	2129691	GB		1984-05-23	Glaxo Group Limited		<input type="checkbox"/>
10	2159151	GB		1985-11-27	Glaxo Group Limited		<input type="checkbox"/>
11	2162842	GB		1986-02-12	Glaxo Group Limited		<input type="checkbox"/>
12	2169265	GB		1986-07-09	Glaxo Group Limited		<input type="checkbox"/>
13	2178965	GB		1987-02-25	Glaxo Group Limited		<input type="checkbox"/>
14	2242134	GB		1991-09-25	Glaxo Group Limited		<input type="checkbox"/>
15	416951	GB		1991-09-01	Hobbs, et al.		<input type="checkbox"/>
16	95/01170	WO		1995-01-12	Glaxo Group Limited		<input type="checkbox"/>
17	99/16766	WO		1999-04-08	Ohshima, et al.		<input type="checkbox"/>
18	99/47505	WO		1999-09-23	Hatzelmann, A., et al.		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10522321
	Filing Date		2005-07-06
	First Named Inventor	BIGGADIKE, et al.	
	Art Unit	1625	
	Examiner Name	Aulakh, Charanjhit	
	Attorney Docket Number	PG4858USw	

	19	01/13953	WO		2001-03-01	Beume, R., et al.		<input type="checkbox"/>
--	----	----------	----	--	------------	-------------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	THORNBUR, C.W.; Isosterism and Molecular Modification in Drug Design; Chemical Society Reviews; 1979; Vol. 8, Iss. 4; pp. 563-580;	<input type="checkbox"/>
	2	IAKOVIDIS, D. ET AL.; Synthesis and beta-andrenoceptor agonist properties of (+/-)-1-(3',4'-dihydroxyphenoxy)-3-(3",4"-dimethoxyphenyl)ethylamino-2-propanol hydrochloride, (+/-)-RO363.HCl, and the (2S)-(-)-isomer"; European Journal of Medicinal Chemistry; 1999; Vol. 34, No. 6; pp. 539-548;	<input type="checkbox"/>
	3	FUJI ET AL.; Novel phosphodiesterase 4 inhibitor T-440 reverse and prevents human bronchial contraction induced by allergen.; Journal of Pharmacology and Experimental Therapeutics; 1998; Vol. 284, No. 1; pp. 162-169;	<input type="checkbox"/>
	4	LANDELLS, ET AL.; Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294 inhibits ex-vivo agonist-induced-cell activation.; European Respiratory Journal (Annu Cong Eur Resp Soc, Geneva); 1998; Vol. 12, Suppl. 28; Abst P2393;	<input type="checkbox"/>
	5	MCHALE, M.M.ET AL.; Expression of Human Recombinant cAMP Phosphodiesterase Isozyme IV Reverses Growth Arrest Phenotypes in Phosphodiesterase-Deficient Yeast; Molecular Pharmacology; 1991; Vol. 39; pp. 109-113;	<input type="checkbox"/>
	6	NICHOLSON, C. D, ET AL.; Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes; Trends in Pharmacological Sciences; 1991; Vol. 12; pp. 19-27;	<input type="checkbox"/>
	7	TORPHY, T.J., ET AL.; Role of Cyclic Nucleotide Phosphodiesterase Isozymes in Intact Canine Trachealis; Molecular Pharmacology; 1991; Vol. 39; pp. 376-384;	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10522321
	Filing Date	2005-07-06
	First Named Inventor	BIGGADIKE, et al.
	Art Unit	1625
	Examiner Name	Aulakh, Charanjhit
	Attorney Docket Number	PG4858USw

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			
<p><sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="http://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.</p>			